Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900432 · ClinicalTrials.gov registry record
Immune Response in Peripheral Blood of Patients With Colon Cancer
A clinical trial, sponsored by University of Arizona.
- Completed
- Registry status
- 67
- Enrollment target
NCT00900432: Completed study, sponsored by University of Arizona.
NCT00900432 is a clinical trial that has completed, run by University of Arizona. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900432 has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells. PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-12 |
What the finished NCT00900432 record still lists
NCT00900432 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00900432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00900432 about?
NCT00900432 is a clinical study titled "Immune Response in Peripheral Blood of Patients With Colon Cancer". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells. PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patient...
What is the current status of trial NCT00900432?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2004-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00900432?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00900432?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia